LY2857785
LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM) .
Product Specifications
CAS Number
1619903-54-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY2857785.html
Purity
99.92
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
CC(C1=C2C=C(C3=NC(N[C@H]4CC[C@H](NC5CCOCC5)CC4)=NC=C3)C=CC2=NN1C)C
Molecular Formula
C26H36N6O
Molecular Weight
448.60
Precautions
H302, H315, H319, H335
References & Citations
[1]Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13 (6) :1442-56. Mol Cancer Ther. 2014 Jun;13 (6) :1442-56.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK7; CDK8; CDK9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
abx525998 96 Tests
Mouse Probable G-protein coupled receptor 22 (GPR22) ELISA Kit
Sign In for Pricing
View Details 
GTR15100578 1 Vial
Lentiviral human PRKAG3 shRNA (UAS) - Lentiviral human PRKAG3 shRNA (UAS) (100)
Sign In for Pricing
View Details 